Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus
Official title: A Randomized Controlled Trial to Assess the Efficacy and Safety of Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus
Status: Recruiting now
Description:
This trial is a prospective, open-label, single-center, split face randomized controlled study comparing 1.5% topical Ruxolitinib cream twice daily (BD) to aqueous cream in treating non-segmental vitiligo (NSV) of the face and neck in patient previous failed to respond to topical tacrolimus 0.1%. Aqueous cream twice daily application will be used as control group treatment. Patients with stable NSV at least 0.5% of their total body surface area (BSA) on the face and neck, as determined by the fingertip method, are screened. Recruited subjects will be asked to review their impression of change of their lesion by the end of the study using a 7-point scale.
Phases: Phase 2, Phase 3.
What is being studied: drugs — Ruxolitinib Cream 1.5%, Aqueous cream.
Who can take part: ages 18 Years to 85 Years, 20 participants planned.
Enrollment status: the registry has not updated this study since its planned completion date, so its current status is unclear. The study started 29 November 2024 and was due to finish 30 January 2026.
Contact: Research Assistant.
Source: ClinicalTrials.gov, NCT06719024 (https://clinicaltrials.gov/study/NCT06719024).
Start date: November 29, 2024
Completion date: January 30, 2026
Organizer: Hospital Authority, Hong Kong
Contact: Research Assistant
Tel.: +85222555885
Email: js83213@hku.hk
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- Does vitiligo increase the risk of skin cancer?
No, it does not. Despite common misconceptions, people with vitiligo are actually at a lower risk of developing skin cancer—including both nonmelanoma skin cancer (NMSC) and mal...
- Do Antioxidant Supplements Help Vitiligo?
Do Antioxidant Supplements Help Vitiligo? Short answer Maybe a little. But probably not in the way most people hope. Antioxidant supplements may offer modest support, especially...
- I have vitiligo: will my children have vitiligo, too?
If you have vitiligo, it’s natural to worry about your children. While there is a genetic component, vitiligo is not a straightforward hereditary disease like eye color or heigh...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.